BWX Technologies, Inc. — Q1 2024 Form 10-Q Summary
Business context and reporting period
BWXT reported results for the three months ended March 31, 2024, compared with the three months ended March 31, 2023. The company operates through Government Operations, which serves U.S. government nuclear, defense, and national laboratory programs, and Commercial Operations, which serves commercial nuclear, medical isotope, and related markets.
Financial performance and key metrics
| Metric | Q1 2024 | Q1 2023 | Change |
|---|---|---|---|
| Revenue | $604.0 million | $568.4 million | 6.3% increase |
| Operating income | $93.0 million | $87.8 million | $5.1 million increase |
| Operating margin | 15.4% | 15.5% | Approximately flat |
| Net income attributable to BWXT | $68.5 million | $61.1 million | 12.1% increase |
| Diluted EPS | $0.75 | $0.67 | Increase of $0.08 |
| Effective tax rate | 22.5% | 23.4% | Decreased 0.9 percentage points |
| Operating cash flow | $33.0 million | $(13.0) million | $46.1 million improvement |
| Capital expenditures | $30.4 million | $29.8 million | $0.6 million increase |
- Government Operations: Revenue increased 5.9% to $487.1 million, but operating income declined 5.4% to $85.7 million. Segment margin decreased to 17.6% from 19.7%.
- Commercial Operations: Revenue increased 7.4% to $117.0 million, while operating income increased to $8.6 million from $1.5 million. Segment margin improved to 7.3% from 1.4%, primarily due to higher service activity, favorable product mix, and lower restructuring costs.
- Interest expense declined to $9.6 million from $10.8 million. Other income increased to $4.2 million, including $9.7 million of gains on non-designated foreign-exchange forward contracts.
- Cash, cash equivalents, and restricted cash totaled $52.0 million at March 31, 2024, down from $81.6 million at December 31, 2023. Total cash, restricted cash, and investments were $62.0 million.
- Working capital increased to $477.8 million from $442.8 million, primarily due to contract-related assets and retainages.
- Total debt was approximately $1.23 billion, consisting of $7.8 million of current debt and $1.22 billion of long-term debt.
Material changes versus the prior comparable period
- Revenue growth was driven by increased advanced-technology design and engineering work, higher Government Operations nuclear-component volume, increased commercial in-plant inspection and maintenance services, and higher medical isotope and fuel activity.
- Government Operations profitability declined because of product-line mix and higher selling, general, and administrative expenses associated with business-development and bid-and-proposal activities.
- Commercial Operations profitability improved materially because of higher revenue, favorable mix, and $2.2 million lower restructuring-related costs.
- Operating cash flow shifted from a use of $13.0 million to a source of $33.0 million, primarily reflecting project cash-flow timing, accounts payable changes, and lower retainage outflows.
- Financing cash flow shifted to a use of $32.2 million from a source of $49.3 million. The change reflected $60.0 million lower net debt borrowings and $20.0 million of common-stock repurchases.
- BWXT declared a quarterly dividend of $0.24 per share, compared with $0.23 per share in Q1 2023.
- Accumulated other comprehensive loss increased to $18.5 million from $7.5 million, largely because of an $11.3 million unfavorable currency-translation adjustment.
Guidance, outlook, risks, contingencies, and unusual items
- The filing does not provide specific full-year revenue, earnings, or cash-flow guidance.
- Remaining performance obligations were approximately $3.64 billion at March 31, 2024; management expects approximately 80% to be recognized by the end of 2025. Government Operations included approximately $416.6 million of unfunded U.S. government backlog.
- Backlog declined from approximately $4.00 billion at December 31, 2023 to $3.64 billion at March 31, 2024. The company noted that backlog depends on government appropriations and may be cancelled, modified, or otherwise altered.
- Approximately $100 million of unexercised options were excluded from backlog and were expected to be awarded in 2024, subject to congressional appropriations.
- Management stated that available cash, borrowing capacity, operating cash generation, and capital-market access should be sufficient for cash requirements for the next 12 months and beyond.
- The credit facility provides a $750 million revolving facility and a $250 million term loan, both scheduled to mature in October 2027. At March 31, 2024, $553.3 million remained available under the revolver for borrowings and letters of credit. BWXT was in compliance with all debt covenants.
- Surety bonds outstanding totaled approximately $114.0 million, and bilateral-facility letters of credit totaled approximately $36.0 million. The company stated that current capacity should support existing requirements for the next 12 months, although capacity and issuance remain subject to surety and lender discretion.
- Underfunded pension and postretirement obligations totaled approximately $101.7 million. Expected contributions for the remainder of 2024 were approximately $3.9 million, subject to additional contributions based on funding and tax considerations.
- The filing reports no material contingencies during the quarter and no material changes to previously disclosed risk factors. Key risks include government budget and appropriations cycles, contract-cost estimates, product mix, project timing, foreign-exchange exposure, capital intensity, and commercial nuclear-market cycles.
Important facts for investors to verify
- Whether Government Operations margins recover from the Q1 decline and whether bid-and-proposal spending affects subsequent quarters.
- The sustainability of the significant Commercial Operations margin improvement and the extent to which it reflects recurring operating performance versus mix and lower restructuring costs.
- Conversion of the $3.64 billion backlog into revenue and cash, including the $416.6 million of unfunded government backlog and appropriations-dependent awards.
- Working-capital requirements associated with $550.1 million of contracts in progress and $81.5 million of retainages.
- Debt reduction, interest costs, revolver availability, and compliance with the 4.00-to-1.00 maximum total net leverage and 3.00-to-1.00 minimum interest-coverage covenants.
- Foreign-exchange effects, including the $460.2 million notional value of FX forwards and the unusually large $9.7 million gain recognized on non-designated contracts in Q1.
- Capital spending, pension and postretirement funding, environmental obligations, and the company’s ability to maintain surety-bond and letter-of-credit capacity.